Figure 5.

Orelabrutinib combined with rituximab effectively inhibited tumor growth in animal models

(A) CB.17/SCID mice were inoculated subcutaneously with 1 × 10⁷ TMD8 cells in 0.1 mL PBS with Matrigel (1:1 ratio); n = 5 per group. (B) 1 mm³ patient tumor tissue was inoculated subcutaneously into the right flank of per mouse. n = 6 per group. Orelabrutinib (10 mg/kg, bid) and rituximab (200 μg/dose, weekly) were administered to the tumor-bearing mice when the tumor volume achieved 150 mm³. Body weight and tumor volume of mice were measured every other day during treatment. (C) Splenocytes of mice from different group were co-cultured with MCL cell line Z138 for 4 h. NK cell cytotoxic activity was then measured using the Nonradioactive Cytotoxicity Assay Kit. Each column represents the mean value of the triplicate experiments. (D) Hematoxylin and eosin (H&E) staining of tumor tissues from TMD8 cell-line-derived xenograft (CDX) tumor model and patient-derived xenograft (PDX) model. Scale bar: 70 μm. ∗p < 0.05 compared with control group, ∗∗p < 0.01 compared with control group, and ∗∗∗p < 0.001 compared with control group; #p < 0.05 compared with rituximab group and ###p < 0.001 compared with rituximab group.